Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Longboard Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the three months ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
Date: August 4, 2022 |
| By: | /s/ Kevin R. Lind |
|
|
| Kevin R. Lind |
|
|
| President and Chief Executive Officer |
|
|
| (Principal Executive Officer) |
Date: August 4, 2022 |
| By: | /s/ Brandi L. Roberts |
|
|
| Brandi L. Roberts |
|
|
| Chief Financial Officer |
|
|
| (Principal Financial and Accounting Officer) |